Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Registry of Toxic Effects of Chemical Substances (RTECS)

Resorcinol

RTECS #

VG9625000

CAS #

108-46-3

Updated

October 2017

Molecular Weight

110.12

Molecular Formula

C6H6O2

Synonyms

1,3-Benzenediol
1,3-Dihydroxybenzene
3-Hydroxycyclohexadien-1-one
3-Hydroxyphenol
Benzene, m-dihydroxy-
C.I. 76505
C.I. Developer 4
C.I. Oxidation Base 31
Developer O
Developer R
Developer RS
Durafur developer G
Fouramine RS
Fourrine 79
Fourrine EW
m-Benzenediol
m-Dihydroxybenzene
m-Dioxybenzene
m-Hydroquinone
m-Hydroxyphenol
Nako TGG
NCI-C05970
Pelagol Grey RS
Pelagol RS
Phenol, m-hydroxy-
RCRA waste number U201
Resorcin
Resorcine
Resorcinol (ACGIH)

Skin and Eye Irritation and References

Route/OrganismDoseEffectReference
eye /rabbit 100 mg severeHPV370 -,-,2004
eye /rabbit 100 mg rinse severeHPV370 -,-,2004
skin /rabbit 500 mgIHFCAY 6,1,1967
skin /rabbit 20 mg/24H moderate85JCAE -,234,1986
skin /rabbit 500 mg severeHPV370 -,-,2004

Mutation Data and Reference

System TestRoute/Organism/TissueDoseReference
Cytogenetic Analysislymphocyte/human80 mg/LARZNAD 32,533,1982
Cytogenetic Analysisother cell types/human40 mg/LARZNAD 32,533,1982
Cytogenetic Analysisovary/hamster1600 mg/LCALEDQ 14,251,1981
Cytogenetic Analysislymphocyte/human0.002 pphVCVGK* -,227,1994
Cytogenetic Analysisovary/hamster1600000 µg/L (+/-enzymatic activation step)HPV370 -,-,2004
DNA Damageother cell types/mouse0.31 mmol/LMUREAV 715,25,2011
DNA Damageliver/rat10 mmol/LCALEDQ 63,47,1992
DNA Damagemammary gland/human50 mg/L/24H (-enzymatic activation step)MUREAV 588,47,2005
DNA Damageother cell types/human1000 µmol/L/24HMUTAEX 31,83,2016
gene conversion and mitotic recombination/Saccharomyes cerevisiae1 gm/LMUREAV 135,109,1984
micronucleus testovary/hamster186 mg/L/24H (-enzymatic activation step)MUREAV 582,116,2005
micronucleus testovary/hamster372 mg/L/3H (+enzymatic activation step)MUREAV 582,116,2005
micronucleus testlung/hamster196 mg/L/3H (+enzymatic activation step)MUREAV 742,11,2012
micronucleus testliver/human377 mg/L/3H (+enzymatic activation step)MUREAV 742,11,2012
micronucleus testlymphocyte/mouse200 mg/L/3HMUREAV 789,7,2015
micronucleus testother cell types/human100 mg/L/3HMUREAV 789,7,2015
mutation in microorganisms/Salmonella typhimurium3600 µg/plate (-enzymatic activation step)HPV370 -,-,2004
mutation in microorganisms/Salmonella typhimurium3600 µg/plate (+enzymatic activation step)HPV370 -,-,2004
mutation in microorganisms/Salmonella typhimurium20 µmol/plate (+/-enzymatic activation step)MUREAV 90,91,1981
specific locus testother cell types/human1000 µmol/L/24HEMMUEG 54,737,2013

Tumorigenic Data and References

Route/OrganismDoseEffectReference
oral/rat lowest published toxic dose: 137200 mg/kg/49W- intermittentTumorigenic: Neoplastic by RTECS criteria

Gastrointestinal: Tumors

Tumorigenic: Increased incidence of tumors in susceptible strains
HPV370 -,-,2004
skin/mouse lowest published toxic dose: 4800 mg/kg/12W- intermittentTumorigenic: Equivocal tumorigenic agent by RTECS criteria

Skin and Appendages: Tumors
CNREA8 19,413,1959

Acute Toxicity Data and References

Route/OrganismDoseEffectReference
In Vitro/Human, leukemia cells Inhibitor Concentration (25 percent kill): 613.4 mg/L/24HIn Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.TIVIEQ 26,1150,2012
In Vitro/Human, melanoma Inhibitor Concentration (50 percent kill): 127.3 mg/L/48HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.FCTOD7 50,2084,2012
In Vitro/Human, monocyte Inhibitor Concentration Low: 4955 mg/L/2HIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,1233,2013
In Vitro/Human, skin Inhibitor Concentration (50 percent kill): >2000 µmol/L/48HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TXAPA9 245,281,2010
In Vitro/Human, skin Inhibitor Concentration (20 percent kill): 55.1 mg/L/21HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 27,314,2013
In Vitro/Human, skin Inhibitor Concentration Low: 55.1 mg/L/4HIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,314,2013
In Vitro/Human, skin Inhibitor Concentration (20 percent kill): 206.0 mg/L/24HIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,1127,2013
In Vitro/Human, skin Inhibitor Concentration (20 percent kill): 500 mg/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 27,1135,2013
In Vitro/Human, skin Inhibitor Concentration Low: 125 mg/L/24HIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,1135,2013
In Vitro/Human, skin Inhibitor Concentration (50 percent kill): 68.58 gm/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 27,1135,2013
intraperitoneal/mouse lethal dose (50 percent kill): 215 mg/kgHPV370 -,-,2004
intravenous/Dog lowest published lethal dose: 700 mg/kgVCVGK* -,227,1994
oral/human lowest published lethal dose: 29 mg/kg34ZIAG -,519,1969
oral/mouse lethal dose (50 percent kill): 200 mg/kgJJTOEX 4,105,1991
oral/rat lowest published lethal dose: 300 mg/kgBehavioral: Convulsions or effect on seizure threshold

Lung, Thorax, or Respiration: Dyspnea
RTOPDW 36,198,2002
oral/rat lethal dose (50 percent kill): 202 mg/kgHPV370 -,-,2004
oral/rat lowest published lethal dose: 215 mg/kgBehavioral: Convulsions or effect on seizure threshold

Lung, Thorax, or Respiration: Other changes

Blood: Hemorrhage
HPV370 -,-,2004
parenteral/frog lowest published lethal dose: 270 mg/kgPeripheral Nerve and Sensation: Spastic paralysis with/without sensory change

Behavioral: Convulsions or effect on seizure threshold

Cardiac: Other changes
AEPPAE 166,437,1932
skin/mouse lowest published lethal dose: 340 mg/kgVCVGK* -,226,1994
skin/rabbit lethal dose (50 percent kill): 3360 mg/kgSkin: After topical application: Primary irritation

Nutritional and Gross Metabolic: Weight loss or decreased weight gain
AIHAAP 37,596,1976
skin/rabbit lethal dose (50 percent kill): 3360 mg/kgSkin: After topical application: Primary irritationHPV370 -,-,2004
skin/rabbit lowest published lethal dose: 3360 mg/kgRTOPDW 36,198,2002
skin/rabbit lethal dose (50 percent kill): 3360 mg/kgVCVGK* -,227,1994
subcutaneous/cat lowest published lethal dose: 110 mg/kgVCVGK* -,227,1994
subcutaneous/cat lowest published lethal dose: 110 mg/kgBehavioral: Convulsions or effect on seizure threshold

Blood: Methemoglobinemia- Carboxhemoglobinemia
AEXPBL 72,241,1913
subcutaneous/guinea pig lowest published lethal dose: 400 mg/kgBehavioral: Excitement

Behavioral: Tetany

Behavioral: Coma
RMSRA6 15,561,1895
subcutaneous/guinea pig lowest published lethal dose: 400 mg/kgVCVGK* -,227,1994
subcutaneous/mouse lethal dose (50 percent kill): 213 mg/kgHPV370 -,-,2004
subcutaneous/rat lowest published lethal dose: 400 mg/kgVCVGK* -,227,1994
subcutaneous/rat lowest published lethal dose: 400 mg/kgBehavioral: Excitement

Behavioral: Tetany

Behavioral: Coma
RMSRA6 15,561,1895
subcutaneous/rat lethal dose (50 percent kill): 450 mg/kgHPV370 -,-,2004

Other Multiple Dose Data and References

Route/OrganismDoseEffectReference
inhalation/rat lowest published toxic concentration: 7800 mg/m3/90D- continuousBlood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)

Blood: Other changes

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
HPV370 -,,2004
oral/mouse lowest published toxic dose: 3000 mg/kg/2W- continuousRelated to Chronic Data: Death in the "MULTIPLE DOSE" data type fieldHPV370 -,,2004
oral/mouse lowest published toxic dose: 115875 mg/kg/103W- intermittentSkin and Appendages: Tumors

Tumorigenic: Active as anti-cancer agent
NTIS** PB93-126381
oral/mouse lowest published toxic dose: 3600 mg/kg/17D- intermittentRelated to Chronic Data: Death in the "MULTIPLE DOSE" data type fieldNTPTR* NTP-TR-403,1992
oral/mouse lowest published toxic dose: 27300 mg/kg/13W- intermittentNutritional and Gross Metabolic: Weight loss or decreased weight gain

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
NTPTR* NTP-TR-403,1992
oral/rat lowest published toxic dose: 25750 mg/kg/103W- intermittentSkin and Appendages: Tumors

Tumorigenic: Active as anti-cancer agent
NTIS** PB93-126381
oral/rat lowest published toxic dose: 150 mg/kg/30D- intermittentEndocrine: Thyroid weight (goiter)

Endocrine: Evidence of thyroid hypofunction
RTOPDW 36,198,2002
oral/rat lowest published toxic dose: 33800 mg/kg/13W- continuousRelated to Chronic Data: Death in the "MULTIPLE DOSE" data type fieldHPV370 -,,2004
oral/rat lowest published toxic dose: 5915 mg/kg/13W- intermittentLiver: Changes in liver weight

Endocrine: Changes in adrenal weight
RTOPDW 36,198,2002
oral/rat lowest published toxic dose: 47320 mg/kg/13W- intermittentLiver: Changes in liver weight

Endocrine: Changes in adrenal weight

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
RTOPDW 36,198,2002
oral/rat lowest published toxic dose: 35000 mg/kg/2W- continuousEndocrine: Evidence of thyroid hypofunction

Endocrine: Changes in thyroid weight

Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)
HPV370 -,,2004
oral/rat lowest published toxic dose: 5400 mg/kg/17D- intermittentEndocrine: Changes in thymus weightNTPTR* NTP-TR-403,1992
skin/rat lowest published toxic dose: 21000 mg/kg/4W- intermittentEndocrine: Thyroid weight (goiter)RTOPDW 36,198,2002
subcutaneous/rat lowest published toxic dose: 20700 mg/kg/69D- intermittentEndocrine: Thyroid weight (goiter)RTOPDW 36,198,2002

Reviews

OrganizationStandardReference
American Conference of Governmental Industrial Hygienists (ACGIH)Threshold Limit Value-time-weighted average 10 ppm;short term exposure limit 20 ppmDTLVS* TLV/BEI,2013
American Conference of Governmental Industrial Hygienists (ACGIH)Threshold Limit Value-Not classifiable as a human carcinogenDTLVS* TLV/BEI,2013
International Agency for Research on Cancer (IARC)Cancer Review:Animal Inadequate EvidenceIMEMDT 15,155,1977
International Agency for Research on Cancer (IARC)Cancer Review:Animal Inadequate EvidenceIMEMDT 71,1119,1999
International Agency for Research on Cancer (IARC)Cancer Review:Human No Adequate DataIMEMDT 15,155,1977
International Agency for Research on Cancer (IARC)Cancer Review:Human No adequate DataIMEMDT 71,1119,1999
International Agency for Research on Cancer (IARC)Cancer Review:Group 3IMEMDT 71,1119,1999
TOXICOLOGY REVIEWMUREAV 47,75,1978
TOXICOLOGY REVIEWJACTDZ 5(3),167,1986
TOXICOLOGY REVIEWMUREAV 543,201,2003
TOXICOLOGY REVIEWEMMUEG 39,69,2002
TOXICOLOGY REVIEWJEADV* 13,14,1999
TOXICOLOGY REVIEWMUREAV 584,1,2005
TOXICOLOGY REVIEWEMCNA* 25,375,2007
TOXICOLOGY REVIEWTXAPA9 243,239,2010
TOXICOLOGY REVIEWMUREAV 723,101,2011
TOXICOLOGY REVIEWMUREAV 653,99,2008
TOXICOLOGY REVIEWREPTED 33,188,2012
TOXICOLOGY REVIEWFCTOD7 49,2495,2011
TOXICOLOGY REVIEWMUREAV 795,7,2016
TOXICOLOGY REVIEWFCTOD7 94,93,2016
TOXICOLOGY REVIEWMUREAV 802,1,I2

Standards and Regulations

OrganizationStandardReference
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV;
Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV
Occupational Exposure Limit-AUSTRALIAtime-weighted average 10 ppm (45 mg/m3), short term exposure limit 20 ppm (90 mg/m3), JUL2008
Occupational Exposure Limit-AUSTRIAMAK-TMW 10 ppm (45 mg/m3), skin, 2007
Occupational Exposure Limit-BELGIUMtime-weighted average 10 ppm (46 mg/m3), MAR2002
Occupational Exposure Limit-BELGIUMshort term exposure limit 20 ppm (91 mg/m3), Skin, MAR2002
Occupational Exposure Limit-DENMARKtime-weighted average 10 ppm (45 mg/m3), skin, MAY2011
Occupational Exposure Limit-ECtime-weighted average 45 mg/m3 (10 ppm), skin, FEB2006
Occupational Exposure Limit-FINLANDtime-weighted average 10 ppm (46 mg/m3), short term exposure limit 20 ppm (91 mg/m3), NOV2011
Occupational Exposure Limit-FRANCEVME 10 ppm (45 mg/m3), FEB2006
Occupational Exposure Limit-HUNGARYtime-weighted average 45 mg/m3, Skin, SEP2000
Occupational Exposure Limit-ICELANDtime-weighted average 10 ppm (45 mg/m3), skin, NOV2011
Occupational Exposure Limit-JAPANs1 sen, MAY2012
Occupational Exposure Limit-KOREAtime-weighted average 10 ppm (45 mg/m3), short term exposure limit 20 ppm (90 mg/m3), 2006
Occupational Exposure Limit-MEXICOtime-weighted average 10 ppm (45 mg/m3);short term exposure limit 20 ppm (90 mg/m3), 2004
Occupational Exposure Limit-NEW ZEALANDtime-weighted average 10 ppm (45 mg/m3), short term exposure limit 20 ppm (90 mg/m3), JAN2002
Occupational Exposure Limit-PERUtime-weighted average 10 ppm (45 mg/m3); short term exposure limit 20 ppm (90 mg/m3), JUL2005
Occupational Exposure Limit-POLANDMAC(time-weighted average) 45 mg/m3, MAC(short term exposure limit) 90 mg/m3, JAN1999
Occupational Exposure Limit-RUSSIAshort term exposure limit 5 mg/m3, Skin, JUN2003
Occupational Exposure Limit-SWEDENtime-weighted average 10 ppm (45 mg/m3), Skin, JUN2005
Occupational Exposure Limit-SWITZERLANDMAK-week 10 ppm, JAN2011
Occupational Exposure Limit-THE NETHERLANDSMAC-TGG 45 mg/m3, 2003
Occupational Exposure Limit-UNITED KINGDOMtime-weighted average 10 ppm (46 mg/m3);short term exposure limit 20 ppm (92 mg/m3), OCT2007

NIOSH Documentation and Surveillance

OrganizationStandardReference
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO RESORCINAL-air10H time-weighted average 10 ppm;short term exposure limit 20 ppmNIOSH* DHHS #92-100,1992
National Occupational Exposure Survey 1983Hazard Code 67220; Number of Industries 30; Total Number of Facilities 6842; Number of Occupations 43; Total Number of Employees Exposed 100792; Total Number of Female Employees Exposed 56465
National Occupational Hazard Survey 1974Hazard Code 67220; Number of Industries 45; Total Number of Facilities 4488; Number of Occupations 42; Total Number of Employees Exposed 40431

Status in Federal Agencies

OrganizationReference
EPA GENETOX PROGRAM 1988, Inconclusive: Mammalian micronucleus
EPA GENETOX PROGRAM 1988, Negative: N crassa-aneuploidy; Histidine reversion-Ames test
EPA TSCA Section 8(b) CHEMICAL INVENTORY
EPA TSCA Section 8(d) unpublished health/safety studies
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NCI Carcinogenesis Studies (gavage);no evidence:mouse,rat
NTP Carcinogenesis Studies (gavagae);no evidence:mouse,rat NTPTR* NTP-TR-403,1992
NTP Carcinogenesis studies; test completed (peer review), October 2000
TOP